Brief: Chemomab Awarded New Patents For CM-101, First-In Class Monoclonal Antibody For Fibro-Inflammatory Diseases
20/02/2024 12:22
Feb 20 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB AWARDED NEW PATENTS FOR CM-101, ITS FIRST-IN
CLASS
MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR
FIBRO-INFLAMMATORY DISEASES
Source text for Eikon: ID:nPn9QgNNa
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update